Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?

Corbus Pharmaceuticals CRBP has emerged as an unusual way for investors to gain exposure to the cannabis space. The company recently announced positive results from an early-stage study on its obesity candidate CRB-913, an oral cannabinoid (CBD)-based small molecule. CRB-913 Gives CRBP's Cannabis Bet a Boost CRB-913 is a second-generation cannabinoid type-1 (CB1) receptor inverse agonist drug being developed for obesity. On Monday, Corbus reported data from the phase Ib CANYON-1 study, which showed that treatment with once-daily CRB-913 achieved statistically significant and clinically meaningful weight loss across all three dose levels — 20 mg, 40 mg and 60 mg — at 12 weeks. The 20-mg and 40-mg doses delivered placebo-adjusted mean weight loss of 2.